The last 12 months witnessed the surge of exciting combination immuno-oncology data, but stakes remain high with clinical translation. With the complexity of immuno-oncology and checkpoint inhibitors, immunomodulating agent utilization, dosing and efficacy remain the critical bottlenecks for IO drug developers. In addition to this, we are still scratching the surface of our understanding of tumor microenvironment and how to look for a predictive biomarker to boost our clinical and therapeutic index confidence.

Returning digitally on January 25-27, the 6^th Tumor Models for Immuno-Oncology Summit 2022 remains dedicated to the preclinical immuno-oncology community – and is the one and only definitive meeting focusing on disease modeling to empower you to:

• Validate your preclinical hypothesis, especially on solid tumors’ microenvironment and biology
• Increase your model utility and toolbox to recapitulate human physiology and immune response
• Drive your translational and clinical decision with improved pharmacokinetics, efficacy and safety readouts
• Enhance your understanding of candidates’ therapeutic index through next gen models
• Share, inspire and meet with your peers and elite model developers to be equipped with the latest technologies and platforms, such as bioinformatics and NGS for a robust predictive biomarker

We are excited about the return of a face-to-face meeting where we can reconnect with the community. Tailored with industry IO model experts including Amgen, Soteria Therapeutics, GSK, Crown, JAX , this 3-days summit will guide and prepare you for the next gen IO development, increasing your clinical relevancy and speed-to-clinic!